Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Watson Pharmaceuticals, Inc. recently received a favorable vote from the Federal Trade Commission (FTC) for its proposed acquisition of the Actavis group of companies. However, Watson Pharma will be required to sell certain products.

These products will be sold to Par Pharmaceuticals, Inc. and Novartis’ (NVS - Snapshot Report) generic division, Sandoz. Currently marketed products that will be sold to Par Pharma include Actavis' generic versions of Johnson & Johnson’s (JNJ - Analyst Report) fentanyl transdermal film (chronic pain), Ani Pharmaceuticals, Inc.’s Reglan (nausea), Kadian (acute pain), and Bayer’s (BAYRY - Analyst Report) Adalat CC (hypertension and angina) among others.

Moreover, Par Pharma will acquire Watson’s pending applications for its generic versions of several products including Shire’s (SHPG - Analyst Report) Adderall XR (attention deficit hyperactivity disorder) and Endo Health’s (ENDP - Analyst Report) Opana ER (chronic pain), among others.

Sandoz will acquire Actavis’ generic versions of drugs including Ativan (anxiety disorders) and GlaxoSmithKline’s (GSK - Analyst Report) Zyban 150 mg (to help quit smoking).

All total, Watson Pharma and Actavis will be selling the rights and assets to 18 drugs and the manufacturing rights to three more.

EC Approval Already Gained

The FTC vote comes a few days after Watson Pharma received the green signal from the European Commission (EC) for its proposed acquisition of Actavis. The EC said that although the acquisition will lead to major changes in the competitive scenario, the combined entity will, nevertheless, continue facing strong competition.

The EC focused on the impact of the acquisition on the markets for drugs like anti-depressants and anti-hypertensives, especially in Denmark, Sweden and the UK.

Acquisition a Smart Strategic Move

Watson Pharma had first announced its intention to acquire Actavis in April 2012 for an upfront payment of €4.25 billion. Actavis stakeholders could also receive an additional consideration depending on the achievement of certain 2012 performance targets. The achievement of these targets would result in the delivery of up to 5.5 million shares of Watson Pharma in 2013. Actavis has a presence in more than 40 countries. The acquisition is slated to close later this month/early next month.

We view the upcoming acquisition of Actavis as a smart strategic move by Watson Pharma. This deal, which is expected to be immediately accretive, should help the company strengthen its presence in the ex-US generics market and expand and strengthen its presence and product portfolio. The acquisition will more than double the company’s commercial position in key European markets as well as emerging markets, including Central and Eastern Europe and Russia.

We note that this acquisition will make Watson Pharma the third largest global generics company. Other players in the generics market include Dr. Reddy’s Laboratories (RDY - Snapshot Report), Mylan (MYL - Analyst Report) and Teva (TEVA - Analyst Report). We currently have a Neutral recommendation on Watson Pharma, which carries a Zacks #2 Rank (short-term ‘Buy’ rating).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%